Literature DB >> 6376062

Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

P Noone.   

Abstract

Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis, while dibekacin and netilmicin are both semisynthetic aminoglycosides. Dibekacin is 3',4'-dideoxykanamycin B and netilmicin is 1-N-ethyl sisomicin. In both cases, these modifications render the agents insusceptible to some of the enzymes found in resistant strains of bacteria which inactivate the parent compounds. Antibacterial activity: All 3 drugs show bactericidal activity against a wide range of Gram-negative bacteria (including E. coli, Enterobacter, Klebsiella and Proteus spp. and Ps. aeruginosa) and also against staphylococci; however, in common with other amino-glycosides, streptococci are usually resistant (except when beta-lactam antibiotics are used in combination) and anaerobic organisms are not sensitive. Sisomicin is closely related structurally to gentamicin Cla, but in vitro studies have shown it to have superior activity to gentamicin against Ps. aeruginosa, closely paralleling the activity of tobramycin, while still possessing the high activity of gentamicin against Serratia and other Gram-negative rods. However, sisomicin is inactivated by virtually all bacterial enzymes which inactivate gentamicin and tobramycin. Nevertheless, it retains useful activity against a number of gentamicin-resistant strains of Ps. aeruginosa which are resistant by non-enzymatic (possibly permeability barrier) mechanisms; in this respect it closely resembles tobramycin. Dibekacin closely resembles tobramycin structurally and in vitro it seems to have a very similar antibacterial spectrum, including activity against some strains of Ps. aeruginosa resistant to gentamicin. Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes; however, it is inactivated by all acetylases, apart from acetylase 3-I. Its spectrum is therefore not as wide as that of amikacin against 'gentamicin-resistant' strains. Nonetheless, it is intrinsically more active than amikacin, weight-for-weight, against sensitive strains, apart possibly from Ps. aeruginosa. In fact, its activity against species of the Enterobacteriaceae and staphylococci sensitive to gentamicin is of the same order as the latter and possibly better for Klebsiella-Enterobacter species. All 3 agents show marked antibacterial synergy with a variety of beta-lactam antibiotics against a range of bacteria. Pharmacokinetically, sisomicin, netilmicin and dibekacin all behave like gentamicin. All 3 drugs are excreted in the urine unchanged and have beta-phase elimination half-lives of around 2 to

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376062     DOI: 10.2165/00003495-198427060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  98 in total

1.  Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients.

Authors:  A Leroy; G Humbert; G Oksenhendler; J P Fillastre
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

2.  In vitro activity of netilmicin compared with gentamicin, tobramycin, amikacin, and kanamycin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Effect of the concentrations of magnesium and calcium on the in-vitro susceptibility of Pseudomonas aeruginosa to gentamicin.

Authors:  D N Gilbert; E Kutscher; P Ireland; J A Barnett; J P Sanford
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

4.  3',4'-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa.

Authors:  H Umezawa; S Umezawa; T Tsuchiya; Y Okazaki
Journal:  J Antibiot (Tokyo)       Date:  1971-07       Impact factor: 2.649

5.  Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic.

Authors:  G H Miller; G Arcieri; M J Weinstein; J A Waitz
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

6.  Comparative activity of sisomicin, gentamicin, kanamycin, and tobramycin.

Authors:  J A Waitz; E L Moss; C G Drube; M J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

7.  Use of aminoglycosides in surgical infections.

Authors:  H H Stone; L D Kolb; C E Geheber; E J Dawkins
Journal:  Ann Surg       Date:  1976-06       Impact factor: 12.969

8.  Comparative clinical trial of sisomicin and gentamicin in serious systemic gram-negative infections.

Authors:  R Lorber; M Danzig; V A Malfitan
Journal:  Clin Ther       Date:  1981       Impact factor: 3.393

9.  Netilmicin therapy of patients with leukaemia or malignant lymphoma.

Authors:  C Geisler; M M Hansen; N Mortensen; P Traun-Pedersen
Journal:  Scand J Infect Dis Suppl       Date:  1980

10.  Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin.

Authors:  C C Crowe; E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more
  6 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa.

Authors:  Pengfei She; Shijia Li; Yaqian Liu; Lanlan Xu; Linying Zhou; Xianghai Zeng; Yimin Li; Shasha Liu; Zehao Li; Zubiar Hussain; Yong Wu
Journal:  Curr Microbiol       Date:  2021-12-14       Impact factor: 2.188

Review 3.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 4.  Bioanalysis of aminoglycosides using high-performance liquid chromatography.

Authors:  Seth K Amponsah; Joseph A Boadu; Daniel K Dwamena; Kwabena F M Opuni
Journal:  ADMET DMPK       Date:  2022-02-14

5.  Draft Genome Sequence of Micromonospora sp. Strain WMMA1996, a Marine Sponge-Associated Bacterium.

Authors:  Doug R Braun; Marc G Chevrette; Deepa D Acharya; Cameron R Currie; Scott R Rajski; Tim S Bugni
Journal:  Genome Announc       Date:  2018-02-22

6.  Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes.

Authors:  Angelia V Bassenden; Linda Dumalo; Jaeok Park; Jonathan Blanchet; Krishnagopal Maiti; Dev P Arya; Albert M Berghuis
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.